CAMBRIDGE, Mass.– SciFluor Life Sciences, a drug discovery and development company harnessing the transformational power of fluorine to accelerate the development of innovative new therapeutics, today announced the availability of one of its novel fluorination technologies for expanded use by industry and academic researchers. Recently developed by Tobias Ritter, Ph.D., co-founder and chief scientific advisor of SciFluor, PhenoFluorTM will now be available through the worldwide Sigma-Aldrich product directory as catalog number SFL0001. Sigma-Aldrich is a leading life science and high technology company whose chemical and biochemical products and kits are used in scientific research, including genomics, biotechnology, pharmaceutical development and the diagnosis of disease.

This is an important milestone for SciFluor, and we are pleased to make this reagent broadly available to scientists worldwide,” said Arthur Hiller, chief executive officer of SciFluor Life Sciences. “PhenoFluor is a novel fluorine technology that we have used to advance our portfolio of Fluoropeutics™ [fluorine-empowered drug candidates] and PET imaging radiotracers for commercialization through industry development partnerships.”

PhenoFluor, a deoxyfluorinating reagent, provides straightforward access to a wide variety of aryl fluorides from phenols in a one-step, high-yield ipso substitution reaction. The method is operationally simple, regiospecific, scalable and compatible with a variety of functional groups including amines, aldehydes and heterocycles. PhenoFluor represents one of a variety of proprietary approaches that the SciFluor scientific team utilizes to incorporate fluorine atoms into clinically-proven drug molecules to improve their pharmacologic profiles as well as to create 18F radiotracers for PET imaging that empower a new level of predictive drug development.

About SciFluor Life Sciences, LLC

SciFluor is harnessing the transformational power of fluorine to enrich pipelines, optimize drug discovery and accelerate the clinical development of innovative new therapies. The company’s approach includes a proprietary portfolio of FluoropeuticsTM, fluorine-enabled development candidates targeting a broad range of therapeutic indications, and novel 18F tracers for empowered PET imaging. SciFluor is funded by Allied Minds, a private equity-funded innovation company that forms, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. The company was founded in 2011 and is based in Cambridge, Mass. For more information, please visit www.scifluor.com.

About Allied Minds, Inc.

Allied Minds is a private equity-funded innovation company that forms, funds, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. We serve as a diversified holding company that supports our businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology commercialization. Our investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and groundbreaking products and services. Our subsidiaries include Allied Minds Devices, BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure, and Spin Transfer Technologies. We don’t just fund the startup. We are the startup. www.alliedminds.com